BPN14770 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
206脆弱X症候群4

206. 脆弱X症候群


臨床試験数 : 108 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05367960
(ClinicalTrials.gov)
November 1, 202229/4/2022An Open-Label Extension Study of BPN14770 in Subjects With Fragile X SyndromeAn Open-Label Extension Study of BPN14770 in Subjects With Fragile X SyndromeFragile X SyndromeDrug: Zatolmilast/ BPN14770Tetra Discovery PartnersNULLEnrolling by invitation12 Years45 YearsMale300Phase 3United States
2NCT05358886
(ClinicalTrials.gov)
November 1, 202227/4/2022A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X SyndromeA Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X SyndromeFragile X SyndromeDrug: BPN14770/ zatolmilast;Drug: PlaceboTetra Discovery PartnersNULLRecruiting18 Years45 YearsMale150Phase 3United States
3NCT05163808
(ClinicalTrials.gov)
March 29, 202215/12/2021A Randomized Study of BPN14770 in Male Adolescents (Aged 12 to < 18 Years) With Fragile X SyndromeA Randomized, Double-blind, Placebo-controlled, Two-Part Study of High and Low Dose BPN14770 in Male Adolescents (Aged 12 to < 18 Years) With Fragile X SyndromeFragile X SyndromeDrug: zatolmilast;Drug: PlaceboTetra Discovery PartnersNULLRecruiting12 Years18 YearsMale150Phase 2/Phase 3United States
4NCT03569631
(ClinicalTrials.gov)
July 9, 201825/5/2018A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X SyndromeA Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study of BPN14770 in Adult Males With Fragile X SyndromeFragile X Syndrome;FXS;Fra(X) SyndromeDrug: BPN14770;Drug: PlaceboTetra Discovery PartnersNULLCompleted18 Years45 YearsMale30Phase 2United States